CJC-1295/ipamorelin: growth hormone

HeLa cells and receptor co-activation

CJC-1295 is a growth hormone-releasing hormone analog, usually shortened to GHRH analog. Ipamorelin acts through the ghrelin receptor. Both can prompt pituitary cells to release growth hormone, through different processes within the cell.

The cleanest demonstration of the receptor idea in this collection used engineered HeLa cells expressing both receptor types. Co-activation produced approximately twice the cAMP response of GHRH-receptor activation alone. cAMP is an internal chemical signal. These were modified cells derived from human cancer tissue, maintained in a dish.

I admire the HeLa experiment’s precision. Clinical conclusions about sleep, recovery or fat loss from CJC-1295 with ipamorelin ask the experiment to answer a much larger question. It measured receptor signaling in cells, using GHRH and ghrelin-related stimulation. A controlled human trial of the named peptide pair still has to be done.

The approximately doubled measurement was cAMP inside engineered cells. The experiment did not measure a doubled clinical benefit.

CJC-1295 and prolonged stimulation

The title of the healthy-adult CJC-1295 study uses the phrase “prolonged stimulation”. After CJC-1295 with DAC alone, mean growth hormone rose two- to ten-fold for at least six days; IGF-1 rose for nine to eleven days. After multiple study doses, IGF-1 remained above baseline for up to 28 days.

DAC, the Drug Affinity Complex, attaches the peptide to albumin in blood. The earlier albumin-conjugate experiments in rats found approximately four-fold greater total growth-hormone release over two hours than with the unmodified releasing hormone, and detected albumin-bound peptide beyond 72 hours.

The difficulty for the proposed pair is that its overall exposure has never been characterized in a controlled human study. Ipamorelin’s intravenous measurements in healthy men describe an approximately two-hour half-life, a very different interval.

The no-DAC form, often called Mod GRF (1-29), lacks the albumin attachment and has a much shorter duration. For me, every claim about CJC-1295 starts with the form used in the study. The DAC study cannot establish the timing or effects of every compound carrying the shorter name.

The clinical questions still waiting

CJC-1295 and ipamorelin together have no controlled human outcome trial, combination pharmacokinetic study or tested comparison with tesamorelin. The review reporting improved muscle tension in steroid-treated mice leaves the benefit at the animal stage.

For CJC-1295 in children, the prolonged-stimulation paper concerns healthy adults. Ipamorelin’s rat bone-growth experiment concerns adult female rats. These sources provide no pediatric treatment result for the pair.

For CJC-1295/ipamorelin and endometriosis, none of the clinical studies listed here tested the combination for that condition. The general hormone mechanism supplies no endometriosis treatment result.

Ipamorelin acetate is the salt form of a research compound. A supplier description cannot establish identity, purity, sterility or clinical effectiveness. This distinction matters for the “CJC/ipa research peptide” shorthand too: it leaves the CJC-1295 form, the actual contents and the untested combination obscured.

Safety questions; community accounts

The clinical safety review of growth hormone secretagogues describes generally favorable short-term tolerability across the class while identifying blood-glucose elevation from reduced insulin sensitivity as a concern. It calls for longer data on cancer and mortality. Those are class findings, with no combination trial to supply the pair’s own adverse-event rates.

Fluid retention, joint discomfort and nerve compression in the wrist are concerns associated with excess growth hormone. Tumor promotion remains a mechanistic concern from raising growth-related signals; a trial has not established cancer risk for this combination.

Community descriptions of better sleep, recovery, hunger, flushing, puffiness, tingling and grogginess are anecdotal accounts rather than clinical evidence. Purity and concurrent changes in exercise or diet were unverified. In these accounts, I distrust confident explanations of harm just as much as confident explanations of benefit.

Drug approval; pharmacy ingredient lists

Neither CJC-1295 nor ipamorelin has approval for human use anywhere. On FDA’s page current as of April 22, 2026, CJC-1295 appears only in the table of withdrawn nominations; ipamorelin acetate appears there and remains in Category 2 under the 503B interim policy. FDA gives no withdrawal date. The withdrawals neither cleared the compounds nor removed the safety concerns about immune reactions, impurities and limited safety data; CJC-1295 also raised concerns about heart effects.

FDA’s pharmacy advisory committee considered ipamorelin on October 29, 2024 and CJC-1295 on December 4, 2024. Neither review constituted drug approval. As of October 1, 2026, FDA had published no rule on either compound. Neither ipamorelin form appears on the 503A Bulks List; withdrawal alone does not decide whether a preparation is permitted. The 503B Category 2 entry provides no interim allowance under that policy. Both peptides are prohibited at all times in sport by WADA.

The FAQ addresses adding tesamorelin to the pairing. The comparison separates the individual studies from the missing combination result.